Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: Long-term follow-up

John V. Kiluk, Quan P Ly, Tammi Meade, Daniel Ramos, Douglas S. Reintgen, Sophie Dessureault, Michelle Davis, Corinne Shamehdi, Charles E. Cox

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) as the definitive nodal staging procedure for breast cancer. SLN biopsy has been proven to cause less morbidity and be more cost effective than complete ALND. Short-term follow-up has shown that lymphatic mapping and SLN have a low false-negative rate, but there is limited data demonstrating long-term outcomes within a large consecutive series of patients. Methods: Retrospective review of a prospective database of breast cancer patients at our institution was performed. The initial mapping of 1,530 patients with invasive breast cancer who demonstrated a negative sentinel node biopsy and no axillary dissection between January 1995 and June 2003 were collated and reviewed to achieve a long-term follow-up. These 1,530 patients were reviewed for follow-up time, local recurrences, distant metastases, and survival. Results: 1,530 consecutively mapped invasive breast cancer patients had a negative SLN biopsy and no ALND. The mean invasive tumor size was 1.40 cm. Of 1,530 patients, 73% (1,121) underwent lumpectomy and 27% (409) underwent mastectomy. Mean follow-up was 4.92 years (range 0-12.0 years). There have been 4 (0.26%) patients presenting with local axillary recurrences, 54 (3.53%) patients presenting with local recurrences in the ipsilateral breast/chest wall, and 24 (1.57%) presenting with distant metastases. Conclusion: These data confirm that SLN biopsy is an effective and safe alternative to ALND for detection of nodal metastases in patients with invasive breast cancer and should be used as the standard tool for nodal staging.

Original languageEnglish (US)
Pages (from-to)S339-S342
JournalAnnals of Surgical Oncology
Volume18
Issue numberSUPPL. 3
DOIs
StatePublished - Dec 1 2011

Fingerprint

Breast Neoplasms
Biopsy
Recurrence
Sentinel Lymph Node Biopsy
Lymph Node Excision
Neoplasm Metastasis
cyhalothrin
Segmental Mastectomy
Mastectomy
Thoracic Wall
Dissection
Breast
Databases
Morbidity
Costs and Cost Analysis
Survival
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer : Long-term follow-up. / Kiluk, John V.; Ly, Quan P; Meade, Tammi; Ramos, Daniel; Reintgen, Douglas S.; Dessureault, Sophie; Davis, Michelle; Shamehdi, Corinne; Cox, Charles E.

In: Annals of Surgical Oncology, Vol. 18, No. SUPPL. 3, 01.12.2011, p. S339-S342.

Research output: Contribution to journalArticle

Kiluk, JV, Ly, QP, Meade, T, Ramos, D, Reintgen, DS, Dessureault, S, Davis, M, Shamehdi, C & Cox, CE 2011, 'Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: Long-term follow-up', Annals of Surgical Oncology, vol. 18, no. SUPPL. 3, pp. S339-S342. https://doi.org/10.1245/s10434-009-0704-1
Kiluk, John V. ; Ly, Quan P ; Meade, Tammi ; Ramos, Daniel ; Reintgen, Douglas S. ; Dessureault, Sophie ; Davis, Michelle ; Shamehdi, Corinne ; Cox, Charles E. / Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer : Long-term follow-up. In: Annals of Surgical Oncology. 2011 ; Vol. 18, No. SUPPL. 3. pp. S339-S342.
@article{2f0e250228fd4e54905a12efc7f6fada,
title = "Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: Long-term follow-up",
abstract = "Objective: Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) as the definitive nodal staging procedure for breast cancer. SLN biopsy has been proven to cause less morbidity and be more cost effective than complete ALND. Short-term follow-up has shown that lymphatic mapping and SLN have a low false-negative rate, but there is limited data demonstrating long-term outcomes within a large consecutive series of patients. Methods: Retrospective review of a prospective database of breast cancer patients at our institution was performed. The initial mapping of 1,530 patients with invasive breast cancer who demonstrated a negative sentinel node biopsy and no axillary dissection between January 1995 and June 2003 were collated and reviewed to achieve a long-term follow-up. These 1,530 patients were reviewed for follow-up time, local recurrences, distant metastases, and survival. Results: 1,530 consecutively mapped invasive breast cancer patients had a negative SLN biopsy and no ALND. The mean invasive tumor size was 1.40 cm. Of 1,530 patients, 73{\%} (1,121) underwent lumpectomy and 27{\%} (409) underwent mastectomy. Mean follow-up was 4.92 years (range 0-12.0 years). There have been 4 (0.26{\%}) patients presenting with local axillary recurrences, 54 (3.53{\%}) patients presenting with local recurrences in the ipsilateral breast/chest wall, and 24 (1.57{\%}) presenting with distant metastases. Conclusion: These data confirm that SLN biopsy is an effective and safe alternative to ALND for detection of nodal metastases in patients with invasive breast cancer and should be used as the standard tool for nodal staging.",
author = "Kiluk, {John V.} and Ly, {Quan P} and Tammi Meade and Daniel Ramos and Reintgen, {Douglas S.} and Sophie Dessureault and Michelle Davis and Corinne Shamehdi and Cox, {Charles E.}",
year = "2011",
month = "12",
day = "1",
doi = "10.1245/s10434-009-0704-1",
language = "English (US)",
volume = "18",
pages = "S339--S342",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer

T2 - Long-term follow-up

AU - Kiluk, John V.

AU - Ly, Quan P

AU - Meade, Tammi

AU - Ramos, Daniel

AU - Reintgen, Douglas S.

AU - Dessureault, Sophie

AU - Davis, Michelle

AU - Shamehdi, Corinne

AU - Cox, Charles E.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objective: Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) as the definitive nodal staging procedure for breast cancer. SLN biopsy has been proven to cause less morbidity and be more cost effective than complete ALND. Short-term follow-up has shown that lymphatic mapping and SLN have a low false-negative rate, but there is limited data demonstrating long-term outcomes within a large consecutive series of patients. Methods: Retrospective review of a prospective database of breast cancer patients at our institution was performed. The initial mapping of 1,530 patients with invasive breast cancer who demonstrated a negative sentinel node biopsy and no axillary dissection between January 1995 and June 2003 were collated and reviewed to achieve a long-term follow-up. These 1,530 patients were reviewed for follow-up time, local recurrences, distant metastases, and survival. Results: 1,530 consecutively mapped invasive breast cancer patients had a negative SLN biopsy and no ALND. The mean invasive tumor size was 1.40 cm. Of 1,530 patients, 73% (1,121) underwent lumpectomy and 27% (409) underwent mastectomy. Mean follow-up was 4.92 years (range 0-12.0 years). There have been 4 (0.26%) patients presenting with local axillary recurrences, 54 (3.53%) patients presenting with local recurrences in the ipsilateral breast/chest wall, and 24 (1.57%) presenting with distant metastases. Conclusion: These data confirm that SLN biopsy is an effective and safe alternative to ALND for detection of nodal metastases in patients with invasive breast cancer and should be used as the standard tool for nodal staging.

AB - Objective: Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) as the definitive nodal staging procedure for breast cancer. SLN biopsy has been proven to cause less morbidity and be more cost effective than complete ALND. Short-term follow-up has shown that lymphatic mapping and SLN have a low false-negative rate, but there is limited data demonstrating long-term outcomes within a large consecutive series of patients. Methods: Retrospective review of a prospective database of breast cancer patients at our institution was performed. The initial mapping of 1,530 patients with invasive breast cancer who demonstrated a negative sentinel node biopsy and no axillary dissection between January 1995 and June 2003 were collated and reviewed to achieve a long-term follow-up. These 1,530 patients were reviewed for follow-up time, local recurrences, distant metastases, and survival. Results: 1,530 consecutively mapped invasive breast cancer patients had a negative SLN biopsy and no ALND. The mean invasive tumor size was 1.40 cm. Of 1,530 patients, 73% (1,121) underwent lumpectomy and 27% (409) underwent mastectomy. Mean follow-up was 4.92 years (range 0-12.0 years). There have been 4 (0.26%) patients presenting with local axillary recurrences, 54 (3.53%) patients presenting with local recurrences in the ipsilateral breast/chest wall, and 24 (1.57%) presenting with distant metastases. Conclusion: These data confirm that SLN biopsy is an effective and safe alternative to ALND for detection of nodal metastases in patients with invasive breast cancer and should be used as the standard tool for nodal staging.

UR - http://www.scopus.com/inward/record.url?scp=82955175556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955175556&partnerID=8YFLogxK

U2 - 10.1245/s10434-009-0704-1

DO - 10.1245/s10434-009-0704-1

M3 - Article

C2 - 19777181

AN - SCOPUS:82955175556

VL - 18

SP - S339-S342

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - SUPPL. 3

ER -